A bone marrow transplant can cure leukemia, and for many patients with high-risk or relapsed disease, it remains the most effective path to long-term remission. But “cure” in leukemia is complicated. About 52% to 56% of patients with acute myeloid leukemia (AML) who receive a transplant from a donor are alive and disease-free at five years, and the likelihood of relapse drops sharply after the first two years. Whether a transplant is the right choice depends on the type of leukemia, how well it responded to initial treatment, and the patient’s overall health.
How a Transplant Fights Leukemia
A bone marrow transplant works against leukemia in two ways. First, high-dose chemotherapy (and sometimes radiation) wipes out the diseased bone marrow, destroying as many leukemia cells as possible. Then donor stem cells are infused to rebuild the blood and immune system from scratch.
The second mechanism is what makes transplant uniquely powerful against leukemia. White blood cells from the donor’s immune system can recognize and attack any leukemia cells that survived the initial treatment. This is called the graft-versus-leukemia effect, and it’s essentially a new immune system hunting down residual cancer. No other treatment offers this kind of ongoing biological surveillance. It’s the main reason donor transplants have curative potential that chemotherapy alone often doesn’t.
Allogeneic vs. Autologous Transplants
There are two broad types of transplant, and they are not interchangeable when it comes to leukemia. An allogeneic transplant uses stem cells from a donor, either a matched family member or an unrelated donor found through a registry. This is the type that produces the graft-versus-leukemia effect and is the standard curative approach for most leukemia patients who need a transplant.
An autologous transplant uses the patient’s own stem cells, collected and stored before high-dose chemotherapy. Because there’s no donor immune system involved, there’s no graft-versus-leukemia effect. Autologous transplants play a role in certain situations, particularly for some patients with AML who have favorable genetic markers and no detectable residual disease. But for most leukemia types, the allogeneic approach offers the stronger chance of a lasting cure.
Who Is a Candidate
Not every leukemia patient needs a transplant, and not every patient is healthy enough for one. Current European guidelines recommend that transplant decisions weigh several factors together: the risk category of the disease, the patient’s other health conditions, the likelihood of transplant success, and whether non-transplant treatments could achieve a similar outcome.
In general, transplant is most clearly beneficial for patients with intermediate or high-risk leukemia, those who relapse after initial chemotherapy, and those whose disease hasn’t responded well to standard treatment. For patients with lower-risk disease who respond well to chemotherapy, transplant may be deferred unless the disease later progresses or develops high-risk genetic features. Age matters too, though the hard cutoffs of earlier decades have softened. Older patients can now receive reduced-intensity conditioning regimens that make transplant feasible into the 60s and sometimes 70s.
Conditioning: Preparing the Body
Before the transplant itself, patients go through a conditioning regimen designed to destroy the existing bone marrow and suppress the immune system enough to accept donor cells. The intensity of this preparation varies.
Full-intensity (myeloablative) conditioning uses high doses of chemotherapy, sometimes combined with total body irradiation. This approach is most common in younger, fitter patients and aims to eliminate as much leukemia as possible before the new cells arrive. Reduced-intensity conditioning lowers those doses by at least 30%, relying more heavily on the donor immune system’s graft-versus-leukemia effect to finish the job. This gentler approach has opened transplant to older patients and those with other health conditions who couldn’t tolerate the full regimen. Both approaches can be curative, but they come with different tradeoffs in terms of side effects and relapse risk.
Relapse Risk Over Time
Relapse is the biggest threat after transplant, and the timing follows a clear pattern. In a large study of AML patients, 26% relapsed during the first year after transplant, and roughly two-thirds of all relapses occurred in that window. By the second year, the relapse rate for that period dropped to about 8%. Beyond two years, only about 7% of the entire transplanted group experienced relapse.
The overall relapse rate at five years was 36%. That means roughly two-thirds of transplanted patients remained relapse-free at five years, which is the closest thing to a practical definition of cure in leukemia. The risk never drops to zero, but late relapses beyond two years are uncommon enough that most patients who reach that milestone can start to feel genuine confidence.
What “Cure” Actually Means
Oncologists rarely use the word “cure” outright. Instead, they talk about complete remission and something called minimal residual disease (MRD) status. MRD testing looks for tiny traces of leukemia cells that standard blood tests can’t detect, sometimes down to one leukemia cell among 100,000 normal cells.
Patients who test MRD-negative before or after transplant have significantly better outcomes. In one study of AML patients with a specific genetic mutation, those who were MRD-negative with low stem cell counts had an excellent prognosis, with no deaths reported during the study period. Patients who were MRD-positive had a median progression-free survival of only 5.5 months. MRD status has become one of the most important tools for predicting who will stay in remission long-term and for deciding how aggressively to treat after transplant.
Graft-Versus-Host Disease
The same donor immune system that fights leukemia can also attack the patient’s healthy tissues. This is graft-versus-host disease (GVHD), and it’s the most significant complication of allogeneic transplant. It can affect the skin, liver, gut, lungs, and other organs.
The good news is that GVHD rates have dropped substantially over the decades as prevention strategies have improved. In the most recent treatment era studied at one major center, moderate-to-severe acute GVHD occurred in about 16% of patients, down from 47% in earlier decades. Severe GVHD (grades III-IV) dropped to 4%. Mild GVHD is manageable and, interestingly, may even be associated with a lower risk of leukemia relapse, since the same immune activation that causes GVHD also fights residual cancer. Severe GVHD, however, carries transplant-related mortality rates above 50% and remains one of the most serious risks of the procedure.
Recovery Timeline
The first 30 days after transplant are focused on engraftment, the point at which the donor stem cells begin producing new blood cells. During this period, patients have essentially no functioning immune system. They’re typically hospitalized or closely monitored, vulnerable to infections, and dependent on blood transfusions.
From day 30 to day 100, doctors watch for GVHD and infection as the new immune system slowly strengthens. Blood counts rise, but immune recovery is far from complete. Most patients remain on immunosuppressive medications and need to avoid crowds, raw foods, and other infection risks. Full immune reconstitution, where the donor immune system is robust enough to handle everyday exposures, typically takes 6 to 12 months or longer. Many patients describe the first year as a gradual return to normalcy, with energy levels and daily function improving in stages rather than all at once.
The Bottom Line on Cure Rates
For AML, the most common adult leukemia requiring transplant, five-year disease-free survival after allogeneic transplant sits around 52%. That number reflects all comers, including patients transplanted with active disease or after multiple relapses. Patients transplanted in first complete remission with favorable genetics and MRD-negative status do considerably better. For chronic myeloid leukemia (CML), transplant was once the only curative option but is now reserved for patients who don’t respond to targeted oral medications. For acute lymphoblastic leukemia (ALL), transplant remains a key curative strategy for high-risk patients and those who relapse.
A bone marrow transplant is not a guarantee, and it carries real risks. But for the right patient at the right time, it offers something that chemotherapy alone often cannot: a realistic chance of living the rest of your life without leukemia.